SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: DRS/A
Document Type: DRS/A
Date Filed: 2025-10-06
Accession Number: 0001493152-25-016953
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315225016953/filename1.htm

Chunk 59 of 87
Word Count: 1385
Character Count: 8749

Document Content:

ordinary course of business; ● whether the transaction with the related person is proposed to be, or was, entered into on terms no less favorable to us than terms that could have been reached with an unrelated third party; ● the purpose of, and the potential benefits to us of, the transaction; and ● any other information regarding the related person transaction or the related person in the context of the proposed transaction that would be material to investors in light of the circumstances of the particular transaction. determining whether to approve, ratify or reject a related person transaction, the audit committee will review all relevant information available to it about such transaction, and it will approve or ratify the related person transaction only if it determines that, under all of the circumstances, the transaction is in, or is not inconsistent with, our best interests. Indemnification of Officers and Directors

Our
Amended and Restated COI contains provisions to indemnify the directors, officers, employees or other agents to the fullest extent permitted
by the Delaware General Corporation Law. These provisions may have the practical effect in certain cases of eliminating the ability of
stockholders to collect monetary damages from directors. We are also a party to indemnification agreements with each of our directors
and executive officers. We believe that these provisions will assist us in attracting or retaining qualified individuals to serve as
our directors and executive officers.

DESCRIPTION
OF CAPITAL STOCK

The
following summary of the capital stock and our Amended and Restated COI and Amended and Restated Bylaws (each to be in effect
as of the effectiveness of the registration statement of which this prospectus forms a part) does not purport to be complete and is qualified
in its entirety by reference to the provisions of applicable law and such documents, which are filed as exhibits to the registration
statement of which this prospectus is a part.

Common
Stock

Voting
Rights. Holders of shares of common stock are entitled to one vote per share held of record on all matters to be voted upon by the
stockholders. Holders of shares of common stock have no cumulative voting rights.

Quorum.
Our Amended and Restated Bylaws provide that the holders of not less than one third (33 1/3 percent) of the outstanding shares of common
stock entitled to vote constitutes a quorum. In the absence of a quorum, any meeting of stockholders may be adjourned, from time to time,
either by the chairman of the meeting or by vote of the holders of a majority of the shares represented thereat, but no other business
shall be transacted at such meeting. Where a separate vote by a class or classes or series is required, except where otherwise provided
by the statute or by our Amended and Restated COI or our Amended and Restated Bylaws, one-third (33 1/3 percent) of the outstanding shares
of such class or classes or series, present in person or represented by proxy, shall constitute a quorum entitled to take action with
respect to that vote on that matter and, except where otherwise provided by the statute or by our Amended and Restated COI or our Amended
and Restated Bylaws, the affirmative vote of the majority (plurality, in the case of the election of directors) of the votes cast, including
abstentions, by the holders of shares of such class or classes or series shall be the act of such class or classes or series.

Dividend
Rights. Holders of shares of common stock are entitled to ratably receive dividends when and if declared by the board of directors
out of funds legally available for that purpose, subject to the provisions of our Amended and Restated COI or our Amended and Restated
Bylaws, any statutory or contractual restrictions on the payment of dividends, and any prior rights and preferences that may be applicable
to any outstanding preferred stock.

Liquidation
Rights. Upon liquidation, dissolution, distribution of assets or other winding up, the holders of common stock are entitled to receive
ratably the assets available for distribution to the stockholders after payment of liabilities and the liquidation preference of any
of our outstanding shares of preferred stock.

Other
Matters. The shares of common stock have no preemptive or preferential right to acquire any of our shares or securities, including
shares or securities held in our treasury. All outstanding shares of our common stock are fully paid and non-assessable.

Preferred
Stock

Our
Amended and Restated COI gives the board of directors the power to issue shares of preferred stock in one or more series without stockholder
approval. The board of directors has the discretion to determine the designations, rights, qualifications, preferences, privileges, and
restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each
series of preferred stock. The purpose of authorizing the board of directors to issue preferred stock and determine its rights and preferences
is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing desirable
flexibility in connection with possible acquisitions and other corporate purposes, could have the effect of making it more difficult
for a third party to acquire, or could discourage a third party from acquiring, a majority of our outstanding voting stock.

Stock
Options

of the date of this prospectus, we had reserved the following shares of common stock for issuance pursuant to stock options under the
2024 Equity Incentive Plan:

shares of our common stock reserved for issuance under stock option agreements issued pursuant
to the 2024 Equity Incentive Plan with a weighted average exercise price of $1.00 per share;
and

shares of our common stock reserved for future issuance under the 2024 Equity Incentive Plan
(which is equal to % of our issued and outstanding common stock immediately after the consummation
of this offering, less the number of outstanding option grants).

Transfer
Agent and Registrar

The
transfer agent and registrar of our common stock is Issuer Direct Corporation.

Representative’s
Warrant

have agreed to issue the Representative’s Warrant to the representative of the underwriters of this offering as a portion of the
underwriting compensation payable in connection with this offering. The Representative’s Warrant shall be exercisable for
shares of our common stock (or 5% of the shares of common stock sold in this offering, including any shares of common stock sold pursuant
to the exercise of the underwriters’ over-allotment option). The Representative’s Warrant shall contain customary “cashless
exercise” provisions and shall be exercisable at any time, and from time to time, in whole or in part, from the first day of the
seventh month after the closing of this offering to the date that is five years from the date of commencement of sales in this offering
at an exercise price equal to the initial public offering price of the shares of common stock. Please see “Underwriting
— Representative’s Warrant” for further information.

Lock-Up
Agreements

Pursuant
to certain “lock-up” agreements, our executive officers, directors and our existing stockholders have agreed, subject to
certain exceptions, not to offer, sell, assign, transfer, pledge, contract to sell, or otherwise dispose of or announce the intention
to otherwise dispose of, or enter into any swap, hedge or similar agreement or arrangement that transfers, in whole or in part, the economic
risk of ownership of, directly or indirectly, engage in any short selling of any common stock or securities convertible into or exchangeable
or exercisable for any common stock, whether currently owned or subsequently acquired, without the prior written consent of the representative
of the underwriters, for a period of six (6) months following the closing of this offering.

addition, we have agreed, subject to certain exceptions, not to offer, sell, assign, transfer, pledge, contract to sell, or otherwise
dispose of or announce the intention to otherwise dispose of, or enter into any swap, hedge or similar agreement or arrangement that
transfers, in whole or in part, the economic risk of ownership of, directly or indirectly, engage in any short selling of any common
stock or securities convertible into or exchangeable or exercisable for any common stock, whether currently owned or subsequently acquired,
without the prior written consent of the representative of the underwriters, for a period of six (6) months following the closing of
this offering.

Delaware
Law and Certain Charter and Bylaw Provisions